Latest Datamonitor Stories

- New research identifies need for transparent communication, additional risk management disclosure and thoughtful regulation NEW YORK, June 22 /PRNewswire/ -- The investment management industry should work to rebuild trust with investors through a 'back-to-basics' client relationship approach, combining improved communication and education, increasing knowledge sharing, and bolstering corporate governance and risk management transparency, reports a new investment management survey...

Sales of hormone replacement therapy have declined recently due to safety concerns, giving non-hormonal drugs for menopausal symptoms an estimated revenue potential of over $535m across the US and five major EU markets in 2007. However, as current developmental drugs do not reduce symptoms substantially, their use could be limited to the minority unable to take hormone replacement therapy. Despite its certainty, women's experiences of the menopause differ considerably. While some women...

Research and Markets (http://www.researchandmarkets.com/research/c84a4e/forecast_insight) has announced the addition of the "Forecast Insight: Parkinson's Disease - Market Upgrade following Evidence of Disease Slowing with Azilect" report to their offering. Stimulated by evidence of disease slowing with Teva/Lundbecks Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR)...

Neurogen's new dopamine agonist aplindore has shown positive results in Phase II trials in the treatment of Parkinson's disease and restless leg syndrome. Datamonitor estimates dopamine agonist sales in these indications were worth $1.5 billion in 2007. However, aplindore's clinical profile suggests that it could be more competitive in the restless leg syndrome than the Parkinson's disease market. Neurogen has announced positive Phase II results for its investigational drug aplindore, in...

Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich. As a result, pharmaceutical companies should weather the financial storm and be able to make significant acquisitions, unlike their biotechnology counterparts. The key impact of the credit crunch on the corporate world is the abrupt loss of cheap debt. During the late...

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success http://www.reportlinker.com/p095770/Commercial-Insight-Inflammatory-Bowel-Disease---Convenience-and-compliance-drive-market-success.html Introduction Several product launches and indication expansion caused substantial sales growth in the seven major...

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. http://www.reportlinker.com/p095767/Forecast-Insight-Parkinsons-Disease---Market-upgrade-following-evidence-of-disease-slowing-with-Azilect.html Introduction Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an...

Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types. In 1997, Biogen Idec/Genentech/Roche/Zenyaku Kogyo's Rituxan (rituximab) - a monoclonal antibody used to...

Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old. Although the breadth of its label is now similar to that of some of its competitors, Datamonitor does not expect that the expanded approval will have a significant impact on sales. Sanofi-Aventis has announced that the FDA has approved the use of Nasacort nasal spray (triamcinolone), the company's treatment of nasal symptoms associated with seasonal and perennial...

Due to heightened concerns over a side effect that can leave users prone to infection, the FDA has flexed its new powers to impose safety warnings on anti-TNF drugs. However, Datamonitor believes that while this action may raise awareness of the side effect, it will not affect drug uptake in the many patients with autoimmune diseases that find relief in these therapies. The FDA has exercised its new authority, under the Food and Drug Administration Amendments Act (FDAA) of 2007, to demand...